Breaking News

Wellesley Island Border Patrol Agents and the Jefferson County Sheriff’s Office Seized Approximately 150 Pounds of Marijuana FEMA Awards Almost $4.5 Million to Manchester-by-the-Sea to Fight Flooding Readout of Deputy Secretary of Defense Dr. Kathleen H. Hicks’ Meeting With U.K. Permanent Under Secretary of Defence David Williams News Release – VIDEO CONSUMER ALERT: Google Voice Identity Theft is On the Rise Remarks by Deputy Secretary of Commerce Don Graves at the NetZero World Industry Summit FDA Provides Update on External Evaluation to Strengthen Agency’s Human Foods Program Laredo Sector Border Patrol arrests a sex offender and a gang member Biden-Harris Administration Invests $981 Million to Expand Market Opportunities for Rural Businesses and Entrepreneurs in 47 States, Guam and the U.S. Virgin Islands

Issued: London UK

In response to events in Japan as a result of the Tohoku Kanto Earthquake and tsunami that devastated Japan’s north east coastline region, GlaxoSmithKline (GSK) is supporting the ongoing relief efforts by working with the Japanese authorities, the Japan Pharmaceutical Manufacturers Association and local NGOs to assist medical support and pharmaceutical donation needs.

As part of the disaster relief program, GSK is donating ¥200 million (approx £1.5million) to the Japanese Red Cross to support the immediate efforts to supply clean water, blankets and food supplies.

The company is also donating cold medicines and oral care products worth ¥ 80 million (approx £600,000) following requests for this type of self-medication products from the authorities.

We are continuing to watch the situation closely and will provide additional support as the situation evolves. GSK is committed to supporting reconstruction efforts as much as possible.

The health and safety of all of the company’s staff based in Japan, particularly those working in the Tohoku region, was accounted for shortly after the earthquake and we continue to offer help and support to all our employees affected by this disaster.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit

GlaxoSmithKline enquiries:


UK Media enquiries:

David Mawdsley

(020) 8047 5502


Claire Brough

(020) 8047 5502


Stephen Rea

(020) 8047 5502


Alexandra Harrison

(020) 8047 5502


Janet Morgan

(020) 8047 5502


David Daley

(020) 8047 5502




US Media enquiries:

Nancy Pekarek

(919) 483 2839


Mary Anne Rhyne

(919) 483 2839


Kevin Colgan

(919) 483 2839


Sarah Alspach

(919) 483 2839



European Analyst/Investor enquiries:

Sally Ferguson

(020) 8047 5543


Gary Davies

(020) 8047 5503


Ziba Shamsi

(020) 8047 3289


US Analyst/ Investor enquiries:

Tom Curry

(215) 751 5419


Jeff McLaughlin

(215) 751 7002

Source link